Contrasting Virios Therapeutics (NASDAQ:VIRI) & Ampio Pharmaceuticals (NYSE:AMPE)

Institutional and Insider Ownership

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Ampio Pharmaceuticals and Virios Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63 million	($11.01)	-0.03
Virios Therapeutics	N/A	N/A	-$5.30 million	($0.27)	-11.93

Virios Therapeutics is trading at a lower price-to-earnings ratio than Ampio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ampio Pharmaceuticals and Virios Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Virios Therapeutics	N/A	-130.33%	-115.00%

Volatility & Risk

Ampio Pharmaceuticals has a beta of 6.65, suggesting that its stock price is 565% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

About Virios Therapeutics

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.